Pharming Group N.V. PHARM

AMS: PHARM | ISIN: NL0010391025   09:34
0,944 EUR (+1,70%)
(+1,70%)   09:34

22 september 2026 · Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 · Persbericht

11 september 2026 · FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S. · Persbericht

9 september 2026 · Pharming Group to participate in September investor conferences · Persbericht

13 augustus 2026 · Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older · Persbericht

7 augustus 2026 · Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky · Persbericht

4 augustus 2026 · Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference · Persbericht

3 augustus 2026 · PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group · Persbericht

31 juli 2026 · Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR) · Persbericht

30 juli 2026 · Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use · Persbericht

16 juli 2026 · Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30 · Persbericht

4 juni 2026 · Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS · Persbericht

2 juni 2026 · Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York · Persbericht

28 mei 2026 · Pharming Group announces results of 2026 Annual General Meeting of Shareholders · Persbericht

22 mei 2026 · European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union · Persbericht

7 mei 2026 · Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 · Persbericht

23 april 2026 · Pharming Group to report first quarter 2026 financial results and provide business update on May 7 · Persbericht

16 april 2026 · Pharming Group announces the 2026 Annual General Meeting of Shareholders · Persbericht

7 april 2026 · Pharming Group to participate in April investor conferences · Persbericht

2 april 2026 · Pharming Group announces the filing of its 2025 Annual Report and Form 20-F · Persbericht

27 maart 2026 · Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older · Persbericht

Mijn selecties